The Efficacy of the Charlson Comorbidity Index and Its Age-Adjusted Version in Forecasting Mortality and Postoperative Outcomes Following Isolated Coronary Artery Bypass Grafting

RECOMMENDED

COPD

Does Chronic Obstructive Pulmonary Disease Impact Outcome after Coronary Artery Bypass Grafting? A Population-Based Retrospective Study in Germany

★ 2 Recommended by Dr Martin Frey, Faculty Member

J Clin Med

Hochhausen N, Sales MC, Ramnath NWM, Billig S, Kork F, Moza A

doi: 10.3390/jcm13175131

COMMENTED

Pulmonary Hypertension

Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL)

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Waligóra M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, Chrzanowski Ł, Błaszczak P, Jaguszewski M, Kuśmierczyk B, Ptaszyńska K, Grześk G, Mizia-Stec K, Malinowska E, Peregud-Pogorzelska M, Lewicka E, Tomaszewski M, Jacheć W, Florczyk M, Mroczek E, Gąsior Z, Pawlak A, Betkier-Lipińska K, Pruszczyk P, Widejko K, Zabłocka W, Kopeć G

doi: 10.1016/j.chest.2024.10.051

Lung Cancer

Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

J Clin Med

Trimarchi G, Pizzino F, Lilli A, De Caterina AR, Esposito A, Dalmiani S, Mazzone A, Di Bella G, Berti S, Paradossi U

doi: 10.3390/jcm13206059

RECOMMENDED

Pulmonary Hypertension

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Heart Lung Transplant

Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV

doi: 10.1016/j.healun.2024.08.018

RECOMMENDED

Pulmonary Fibrosis

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Thorax

Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, Healy J, Rubin JL, Brookhart MA

doi: 10.1136/thorax-2023-220558

RECOMMENDED

Tuberculosis

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID, STREAM study collaborators

doi: 10.1016/S2213-2600(24)00186-3

COMMENTED

Sleep Apnea

Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 0 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Benjafield AV, Pepin JL, Cistulli PA, Wimms A, Lavergne F, Sert Kuniyoshi FH, Munson SH, Schuler B, Reddy Badikol S, Wolfe KC, Willes L, Kelly C, Kendzerska T, Johnson DA, Heinzer R, Lee CH, Malhotra A, medXcloud Group

doi: 10.1016/S2213-2600(25)00002-5

RECOMMENDED

COPD

Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Calzetta L, Pistocchini E, Laitano R, Gholamalishahi S, Cazzola M, Rogliani P

doi: 10.1016/j.rmed.2025.107956

Pulmonary Fibrosis

Donor age over 55 is associated with worse outcome in lung transplant recipients with idiopathic pulmonary fibrosis

BMC Pulm Med

Moneke I, Ogutur ED, Kornyeva A, Fähndrich S, Schibilsky D, Bierbaum S, Czerny M, Stolz D, Passlick B, Jungraithmayr W, Frye BC

doi: 10.1186/s12890-024-03317-x

Related content

Does Chronic Obstructive Pulmonary Disease Impact Outcome after Coronary Artery Bypass Grafting? A Population-Based Retrospective Study in Germany

Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL)

Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies

Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging

Donor age over 55 is associated with worse outcome in lung transplant recipients with idiopathic pulmonary fibrosis